DG15B8Z
Brachytherapy Thyroid to None with Iridium 192 (Ir-192), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | G Endocrine System |
| Operation | 1 Brachytherapy |
| Body Part | 5 Thyroid |
| Approach | B Low Dose Rate (LDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for the endocrine system involves placing a radioactive source directly into or immediately next to a gland, such as the thyroid or an adrenal gland, rather than aiming radiation at it from outside the body. Because the source sits so close to the target tissue, it can deliver a concentrated dose to the tumor while limiting exposure to surrounding structures.
This approach is used less often for endocrine tumors than external beam therapy, but it may be chosen when a tumor is well localized and accessible, or when a patient has already received prior external radiation and cannot tolerate additional beam exposure to the area. The radioactive material can be left in place temporarily or permanently, depending on the type of source and the treatment plan developed by the radiation oncology team.
Patients typically undergo a minor procedure to place the source, followed by a defined period during which the radiation is active, after which temporary sources are removed.
Anatomy & Axis Detail
Thyroid
The thyroid gland's central neck location and radiosensitivity make it a distinctive site for brachytherapy, in which a sealed radioactive source is placed directly into or adjacent to thyroid tissue rather than delivered from an external beam. This localized approach may be used for recurrent thyroid malignancy or when prior external radiation limits further dose to surrounding tissue, allowing a concentrated dose to residual tumor while sparing the trachea, esophagus, and parathyroid glands embedded nearby. It is distinct from radioactive iodine therapy, which works through selective uptake by thyroid tissue rather than physical source placement. Because the gland is superficial and accessible, image-guided or intraoperative placement is feasible, and documentation should distinguish this technique from both iodine ablation and external beam approaches to the same organ.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
The operative note must document direct placement of a radioactive source in or adjacent to the endocrine gland, along with the specific gland treated, to support a code from this family. Coders should confirm whether the source was temporary or permanent, since this can affect qualifier selection and whether a separate removal procedure needs to be captured later. A common mistake is confusing brachytherapy with radioactive iodine ablation for thyroid disease, which is often administered orally or systemically rather than through direct implantation and may not be coded as a procedure in this section at all. Another pitfall is failing to code the placement device or applicator separately when the documentation calls for it under coding guidelines.